Home LiteratureArticle Details
PMID: 25102416 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.

PLoS computational biology ·Vol. 10 ·No. 8 ·2014-08-00 ·Pages e1003665

Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, Graubert TA, Walter MJ, Ellis MJ, Schierding W, DiPersio JF, Ley TJ, Mardis ER, Wilson RK, Ding L

Abstract

The sensitivity of massively-parallel sequencing has confirmed that most cancers are oligoclonal, with subpopulations of neoplastic cells harboring distinct mutations. A fine resolution view of this clonal architecture provides insight into tumor heterogeneity, evolution, and treatment response, all of which may have clinical implications. Single tumor analysis already contributes to understanding these phenomena. However, cryptic subclones are frequently revealed by additional patient samples (e.g., collected at relapse or following treatment), indicating that accurately characterizing a tumor requires analyzing multiple samples from the same patient. To address this need, we present SciClone, a computational method that identifies the number and genetic composition of subclones by analyzing the variant allele frequencies of somatic mutations. We use it to detect subclones in acute myeloid leukemia and breast cancer samples that, though present at disease onset, are not evident from a single primary tumor sample. By doing so, we can track tumor evolution and identify the spatial origins of cells resisting therapy.

MeSH Terms
Breast Neoplasms/genetics Clonal Evolution/genetics Computational Biology/methods Female Gene Frequency/genetics Humans Leukemia, Myeloid, Acute/genetics Models, Statistical Mutation/genetics Neoplasms/classification,genetics Neoplastic Processes
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Miller Christopher A
The Genome Institute, Washington University, St. Louis, Missouri, United States of America.
White Brian S
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Dees Nathan D
The Genome Institute, Washington University, St. Louis, Missouri, United States of America.
Griffith Malachi
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America.
Welch John S
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Griffith Obi L
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Vij Ravi
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Tomasson Michael H
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Graubert Timothy A
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America; Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Walter Matthew J
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Ellis Matthew J
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Schierding William
Liggins Institute, Auckland, New Zealand.
DiPersio John F
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Ley Timothy J
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Mardis Elaine R
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Wilson Richard K
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Ding Li
The Genome Institute, Washington University, St. Louis, Missouri, United States of America; Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Genetics, Washington University, St. Louis, Missouri, United States of America; Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America.
References (52)
52 references, click to expand
  1. Detection of clinically relevant copy number variants with whole-exome sequencing.
    Hum Mutat. 2013 Oct;34(10):1439-48 PMID: 23893877
  2. Bayesian estimation of beta mixture models with variational inference.
    IEEE Trans Pattern Anal Mach Intell. 2011 Nov;33(11):2160-73 PMID: 21422484
  3. Allele-specific copy number analysis of tumors.
    Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5 PMID: 20837533
  4. The origin and evolution of mutations in acute myeloid leukemia.
    Cell. 2012 Jul 20;150(2):264-78 PMID: 22817890
  5. Genome remodelling in a basal-like breast cancer metastasis and xenograft.
    Nature. 2010 Apr 15;464(7291):999-1005 PMID: 20393555
  6. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing.
    Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 PMID: 18723673
  7. THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data.
    Genome Biol. 2013 Jul 29;14(7):R80 PMID: 23895164
  8. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.
    Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 PMID: 20947487
  9. Opening Pandora's Box--the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing.
    Curr Opin Genet Dev. 2012 Feb;22(1):3-9 PMID: 22386266
  10. Macrostate data clustering.
    Phys Rev E Stat Nonlin Soft Matter Phys. 2003 May;67(5 Pt 2):056704 PMID: 12786319
  11. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.
    Genome Res. 2012 Mar;22(3):568-76 PMID: 22300766
  12. Absolute quantification of somatic DNA alterations in human cancer.
    Nat Biotechnol. 2012 May;30(5):413-21 PMID: 22544022
  13. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing.
    PLoS Genet. 2014 Jul 10;10(7):e1004462 PMID: 25010716
  14. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
    Blood. 2012 Aug 2;120(5):1060-6 PMID: 22529291
  15. Genetic variegation of clonal architecture and propagating cells in leukaemia.
    Nature. 2011 Jan 20;469(7330):356-61 PMID: 21160474
  16. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Cancer Cell. 2010 Mar 16;17(3):225-34 PMID: 20171147
  17. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-892 PMID: 22397650
  18. Intratumor heterogeneity: seeing the wood for the trees.
    Sci Transl Med. 2012 Mar 28;4(127):127ps10 PMID: 22461637
  19. Minor clone provides a reservoir for relapse in multiple myeloma.
    Leukemia. 2013 Feb;27(2):473-81 PMID: 22874878
  20. PyClone: statistical inference of clonal population structure in cancer.
    Nat Methods. 2014 Apr;11(4):396-8 PMID: 24633410
  21. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate.
    Nucleic Acids Res. 2012 May;40(9):e69 PMID: 22302147
  22. Emerging landscape of oncogenic signatures across human cancers.
    Nat Genet. 2013 Oct;45(10):1127-33 PMID: 24071851
  23. DGIdb: mining the druggable genome.
    Nat Methods. 2013 Dec;10(12):1209-10 PMID: 24122041
  24. Inferring clonal evolution of tumors from single nucleotide somatic mutations.
    BMC Bioinformatics. 2014 Feb 01;15:35 PMID: 24484323
  25. Inferring tumor progression from genomic heterogeneity.
    Genome Res. 2010 Jan;20(1):68-80 PMID: 19903760
  26. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.
    Cell. 2012 Mar 2;148(5):873-85 PMID: 22385957
  27. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Blood. 2002 Aug 1;100(3):1014-8 PMID: 12130516
  28. Efficient uncertainty minimization for fuzzy spectral clustering.
    Phys Rev E Stat Nonlin Soft Matter Phys. 2009 Nov;80(5 Pt 2):056705 PMID: 20365094
  29. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  30. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    J Clin Oncol. 2012 Feb 1;30(4):433-40 PMID: 22215752
  31. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
    Nat Commun. 2014;5:2997 PMID: 24429703
  32. Clonal competition with alternating dominance in multiple myeloma.
    Blood. 2012 Aug 2;120(5):1067-76 PMID: 22498740
  33. Cancer heterogeneity: implications for targeted therapeutics.
    Br J Cancer. 2013 Feb 19;108(3):479-85 PMID: 23299535
  34. Tumour evolution inferred by single-cell sequencing.
    Nature. 2011 Apr 7;472(7341):90-4 PMID: 21399628
  35. Recurring mutations found by sequencing an acute myeloid leukemia genome.
    N Engl J Med. 2009 Sep 10;361(11):1058-66 PMID: 19657110
  36. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Br J Cancer. 2010 Oct 12;103(8):1139-43 PMID: 20877357
  37. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.
    Leukemia. 2013 Jun;27(6):1275-82 PMID: 23443460
  38. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.
    Cell. 2012 Mar 2;148(5):886-95 PMID: 22385958
  39. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
    Nature. 2012 Apr 04;486(7403):395-9 PMID: 22495314
  40. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
    Cancer Cell. 2010 Jan 19;17(1):77-88 PMID: 20129249
  41. Runx1 and p21 synergistically limit the extent of hair follicle stem cell quiescence in vivo.
    Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4634-9 PMID: 23487742
  42. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    J Clin Oncol. 2010 Aug 1;28(22):3636-43 PMID: 20567020
  43. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Science. 2013 May 3;340(6132):622-6 PMID: 23558173
  44. Integrated genomic characterization of endometrial carcinoma.
    Nature. 2013 May 2;497(7447):67-73 PMID: 23636398
  45. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
    Cell. 2013 Feb 14;152(4):714-26 PMID: 23415222
  46. The life history of 21 breast cancers.
    Cell. 2012 May 25;149(5):994-1007 PMID: 22608083
  47. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.
    Genome Res. 2012 Oct;22(10):1995-2007 PMID: 22637570
  48. Variational learning for finite Dirichlet mixture models and applications.
    IEEE Trans Neural Netw Learn Syst. 2012 May;23(5):762-74 PMID: 24806125
  49. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control.
    Biomed Res Int. 2013;2013:915636 PMID: 24303503
  50. Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
    Nature. 2010 Oct 28;467(7319):1114-7 PMID: 20981102
  51. Clonal evolution in cancer.
    Nature. 2012 Jan 18;481(7381):306-13 PMID: 22258609
  52. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
    Nature. 2012 Jan 11;481(7382):506-10 PMID: 22237025
Article Info
Journal
PLoS computational biology
Abbr.
PLoS Comput Biol
ISSN
1553-7358
Published
2014-08-00
Epub
2014-00-07
Pages
e1003665
Language
English
Region
United States
NLM ID
101238922
PMCID
PMC4125065
Subset
IM
Grants
NHGRI NIH HHS · U01 HG006517 · United States
NCI NIH HHS · P50 CA171963 · United States
NCI NIH HHS · K12 CA167540 · United States
NCI NIH HHS · R01 CA180006 · United States
NHGRI NIH HHS · U01HG006517 · United States
NCI NIH HHS · P01 CA101937 · United States
NHGRI NIH HHS · U54HG003079 · United States
NCI NIH HHS · P50CA171063 · United States
NCI NIH HHS · 1K12CA167540 · United States
NHGRI NIH HHS · U54 HG003079 · United States
NCATS NIH HHS · UL1 TR000448 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]